Symbicort: Advanced Dual-Action Asthma and COPD Control
| Product dosage: 100 mcg + 6 mcg | |||
|---|---|---|---|
| Package (num) | Per inhaler | Price | Buy |
| 1 | $46.35 | $46.35 (0%) | 🛒 Add to cart |
| 2 | $36.78 | $92.70 $73.55 (21%) | 🛒 Add to cart |
| 3 | $32.24
Best per inhaler | $139.04 $96.73 (30%) | 🛒 Add to cart |
| Product dosage: 200 mcg + 6 mcg | |||
|---|---|---|---|
| Package (num) | Per inhaler | Price | Buy |
| 1 | $50.38 | $50.38 (0%) | 🛒 Add to cart |
| 2 | $45.84 | $100.76 $91.69 (9%) | 🛒 Add to cart |
| 3 | $41.31
Best per inhaler | $151.14 $123.93 (18%) | 🛒 Add to cart |
| Product dosage: 400 mcg + 6 mcg | |||
|---|---|---|---|
| Package (num) | Per inhaler | Price | Buy |
| 1 | $55.42 | $55.42 (0%) | 🛒 Add to cart |
| 2 | $50.38 | $110.83 $100.76 (9%) | 🛒 Add to cart |
| 3 | $44.33
Best per inhaler | $166.25 $133.00 (20%) | 🛒 Add to cart |
Synonyms | |||
Symbicort is a prescription combination inhaler designed for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). It integrates a long-acting beta2-adrenergic agonist (LABA) and an inhaled corticosteroid (ICS) into a single device, offering both rapid bronchodilation and sustained anti-inflammatory action. This dual mechanism provides comprehensive airway management, reduces exacerbation frequency, and supports improved daily symptom control in appropriate patient populations. Clinical evidence supports its efficacy in enhancing lung function and quality of life when used as directed under medical supervision.
Features
- Contains budesonide (an inhaled corticosteroid) and formoterol (a long-acting bronchodilator)
- Available in multiple strength combinations to allow for individualized dosing
- Delivered via a pressurized metered-dose inhaler (pMDI) with a built-in dose counter
- Rapid onset of action with formoterol providing relief within 1–3 minutes
- Designed for twice-daily maintenance therapy
- Compatible with optional spacer devices for improved lung deposition
Benefits
- Provides both immediate and long-term control of airway constriction and inflammation
- Reduces the frequency and severity of asthma and COPD exacerbations
- Improves overall lung function measurements, including FEV1
- Enhances ability to perform daily activities with reduced breathlessness
- Minimizes the need for rescue inhaler use through proactive management
- Supports adherence through simplified, twice-daily dosing regimen
Common use
Symbicort is indicated for the maintenance treatment of asthma in patients aged 6 years and older, and for the maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema. It is not intended for immediate relief of acute bronchospasm. In asthma, it is used to control symptoms and prevent exacerbations; in COPD, it helps improve lung function and reduce exacerbations. Physicians may also prescribe it for off-label uses under specific clinical circumstances, though such applications should be carefully justified and monitored.
Dosage and direction
Dosage must be individualized based on disease severity and patient response. For asthma maintenance in patients 12 years and older: 2 inhalations twice daily (either 80/4.5 mcg or 160/4.5 mcg strength). For children 6 to under 12 years: 2 inhalations twice daily of the 80/4.5 mcg strength. For COPD: 2 inhalations of the 160/4.5 mcg strength twice daily. Administer at approximately the same times every day, about 12 hours apart. Shake well before each inhalation. Rinse mouth with water after each use to reduce the risk of oral candidiasis. Do not exceed prescribed dosage.
Precautions
Patients should be advised that Symbicort is not a rescue medication and should not be used for treating acute symptoms. Caution is advised in patients with cardiovascular disorders, convulsive disorders, thyrotoxicosis, diabetes, ketoacidosis, and in those unusually responsive to sympathomimetic amines. Systemic corticosteroid effects may occur, particularly at higher doses over prolonged periods; monitor for adrenal suppression. Be alert for signs of paradoxical bronchospasm. Patients should be instructed on proper inhaler technique to ensure optimal drug delivery. Periodic assessments of growth are recommended in pediatric patients.
Contraindications
Symbicort is contraindicated in patients with a known hypersensitivity to budesonide, formoterol, or any component of the formulation. It should not be used for the primary treatment of status asthmaticus or other acute episodes where intensive measures are required. Use is contraindicated in patients experiencing an acute exacerbation of COPD or asthma that is intensive care-bound.
Possible side effects
Common side effects may include headache, throat irritation, nasopharyngitis, upper respiratory tract infection, sinusitis, and oral candidiasis. Less frequently, patients may experience palpitations, chest pain, tachycardia, nervousness, tremor, cough, hoarseness, or dysphonia. Long-term use of ICS may be associated with reduced bone mineral density, cataracts, glaucoma, and adrenal suppression. Although rare, hypersensitivity reactions and paradoxical bronchospasm may occur. Patients should report any unusual or severe symptoms to their healthcare provider.
Drug interaction
Concomitant use with other beta-adrenergic drugs may potentiate sympathetic effects. Caution is advised with MAO inhibitors, tricyclic antidepressants, and drugs that prolong the QTc interval. Ketoconazole and other potent CYP3A4 inhibitors may increase budesonide plasma concentrations. Diuretics may enhance hypokalemic effects. Use with other corticosteroids may increase the risk of systemic effects. Healthcare providers should review the patient’s full medication list to avoid potential interactions.
Missed dose
If a dose is missed, it should be taken as soon as remembered, unless it is almost time for the next scheduled dose. In that case, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed one. Maintaining a consistent dosing routine is important for optimal control of symptoms.
Overdose
Overdosage may lead to exaggerated pharmacologic effects such as tachycardia, arrhythmias, tremor, headache, muscle cramps, dry mouth, nausea, and hyperglycemia. Hypokalemia may also occur. Supportive measures should be instituted based on symptoms. Cardiac monitoring is recommended in cases of significant overdose. There is no specific antidote; treatment should be symptomatic and supportive.
Storage
Store at room temperature between 15°C and 30°C (59°F and 86°F). Do not freeze. Keep the canister away from direct heat or sunlight. Store with the mouthpiece down. Keep out of reach of children and pets. Discard the inhaler when the dose counter reads “0” or 3 months after removal from the foil pouch, whichever comes first. Do not puncture or incinerate, even when empty.
Disclaimer
This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for personalized recommendations and before starting or changing any medication regimen. Individual patient responses and needs may vary.
Reviews
Clinical studies and patient reports generally reflect satisfaction with Symbicort’s efficacy in controlling persistent asthma and COPD symptoms. Many users note improved exercise tolerance and reduced exacerbation frequency. Some report mild side effects such as hoarseness or oral thrush, which often resolve with proper technique and oral rinsing. Healthcare professionals appreciate its dual-action formulation and flexibility in dosing. As with any medication, individual experiences may vary, and ongoing communication with a prescriber is essential for optimal outcomes.